Your browser doesn't support javascript.
loading
Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan.
Nakano, Yuki; Kurano, Makoto; Morita, Yoshifumi; Shimura, Takuya; Yokoyama, Rin; Qian, Chungen; Xia, Fuzhen; He, Fan; Kishi, Yoshiro; Okada, Jun; Yoshikawa, Naoyuki; Nagura, Yutaka; Okazaki, Hitoshi; Moriya, Kyoji; Seto, Yasuyuki; Kodama, Tatsuhiko; Yatomi, Yutaka.
Afiliação
  • Nakano Y; Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
  • Kurano M; Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan. kurano-tky@umin.ac.jp.
  • Morita Y; Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. kurano-tky@umin.ac.jp.
  • Shimura T; Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
  • Yokoyama R; Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
  • Qian C; Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
  • Xia F; The Key Laboratory for Biomedical Photonics of MOE At Wuhan National Laboratory for Optoelectronics - Hubei Bioinformatics and Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Tec
  • He F; Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Shenzhen, Guangdong, People's Republic of China.
  • Kishi Y; Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Shenzhen, Guangdong, People's Republic of China.
  • Okada J; Business Planning Department, Sales and Marketing Division, Medical and Biological Laboratories Co, Ltd, Tokyo, Japan.
  • Yoshikawa N; Business Planning Department, Sales and Marketing Division, Medical and Biological Laboratories Co, Ltd, Tokyo, Japan.
  • Nagura Y; Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
  • Okazaki H; Department of Blood Transfusion, The University of Tokyo Hospital, Tokyo, Japan.
  • Moriya K; Department of Blood Transfusion, The University of Tokyo Hospital, Tokyo, Japan.
  • Seto Y; Department of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan.
  • Kodama T; Department of Gastrointestinal Surgery, The University of Tokyo, Tokyo, Japan.
  • Yatomi Y; Laboratory for Systems Biology and Medicine, The University of Tokyo, Tokyo, Japan.
Sci Rep ; 11(1): 2776, 2021 02 02.
Article em En | MEDLINE | ID: mdl-33531605
ABSTRACT
The accurate and prompt diagnosis of SARS-CoV-2 infection is required for the control and treatment of the coronavirus infection disease 2019 (COVID-19). In this study, we aimed to investigate the time courses of the anti-severe acute corona respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and IgG titers and to evaluate the sensitivity and specificity of such tests according to the specific day after the onset of COVID-19 among a patient population in Japan. We measured the titers of SARS-CoV-2 IgM and IgG in sera from 105 subjects, including 26 symptomatic COVID-19 patients, using chemiluminescent immunoassay (CLIA) methods utilizing magnetic beads coated with SARS-CoV-2 nucleocapsid protein and spike protein. The results of a ROC analysis suggested the possibility that the cutoff values in Japan might be lower than the manufacturer's reported cutoff (10 AU/mL) 1  AU/mL for IgM and 5  AU/mL for IgG. The sensitivity of the test before Day 8 after symptom onset was less than 50%; at Days 9-10, however, we obtained a much higher sensitivity of 81.8% for both IgM and IgG. At 15 days or later after symptom onset, the SARS-CoV-2 IgG test had a sensitivity of 100%. These results suggest that if the number of days since disease onset is taken into consideration, these antibody tests could be very useful for the diagnosis of COVID-19 and similar diseases.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Imunoglobulina M / SARS-CoV-2 / COVID-19 / Especificidade de Anticorpos Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Imunoglobulina M / SARS-CoV-2 / COVID-19 / Especificidade de Anticorpos Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article